We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Salivary Urea Nitrogen Dipstick Detects Acute Kidney Disease

By LabMedica International staff writers
Posted on 02 Jan 2019
Early recognition of acute kidney injury (AKI) is an essential step in allowing timely treatment in efforts to improve patient outcomes from this potentially reversible condition.

The diagnosis of AKI is highly dependent on the measurement of serum creatinine (SCr), which is almost universally available in high-income countries; however it is often not available in less privileged health care settings.

Scientists collaborating with the University of Malawi College of Medicine (Blantyre, Malawi) enrolled 310 patients between September 21 and December 11, 2015, in a prospective observational study. More...
Those include in the study were more than 20 weeks’ gestation or less than 6 weeks postpartum presenting with conditions predetermined as being at risk of leading to AKI. The mean age of the entire cohort was 25.9 ± 6.45 years.

Baseline clinical data were recorded, and screening for kidney disease (community-acquired) was undertaken with a SCr alongside simultaneous measurement of Salivary Urea Nitrogen (SUN) using a dipstick. SCr and urea were measured by the Jaffe and urease methods, respectively, using either a Flexor Junior Clinical Chemistry Analyzer or a Mindray Chemistry Analyzer BS-120.

The investigators reported that of the patients, 23 (7.6%) had AKI, stage 1 in 47.8%, most commonly due to preeclampsia/eclampsia. Mean presenting SCr values were 108.8 ± 21.8 μmol/L (1.23 ± 0.25 mg/dL), 118 ± 34.45 μmol/L (1.33 ± 0.39 mg/dl), and 136.1 ± 30.4 μmol/L (1.54 ± 0.34 mg/dL) in AKI stages 1 to 3 respectively. SUN greater than 14 mg/dL had a sensitivity of 12.82% and a specificity of 97.33% to detect acute kidney disease. The area under the receiver operating characteristic curve was 0.551. In patients with normal SUN on admission, perinatal mortality was 11.8%, and was 25.0% if SUN was > 14 mg/dL.

The authors concluded that in their study, measuring SUN using a dipstick was specific but insensitive when used to diagnose obstetric-related acute kidney disease in Malawi. Low salivary urea concentrations in this cohort, in combination with the reduced accuracy of the dipstick at lower levels of BUN, are the likely main drivers for the lack of sensitivity seen in the study. A modified SUN dipstick with increased sensitivity at the lower ranges of SUN is currently under development, with plans to test this in both pregnant and non-pregnant patients with kidney disease. The study was published in the January 2019 issue of the journal Kidney International Reports.

Related Links:
University of Malawi College of Medicine


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.